semaglutide bone density loss Weight induced loss: mechanism of action and clinical implications New findings suggest Ozempic may

doi: 10.12691/jfnr-3-9-6 6 StefaniMRigacciS

McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al

Monitoring of serious adverse events during the trial Multiple strategies were used to monitor serious adverse events in both trials and reporting procedures were refined during the trial as necessary (see Table 3)

10.1038/s41586-020-2971-8 Nature 120 SchnorrS

Under continuous weekly exposure the receptor desensitizes: semaglutide is a full beta-arrestin recruiter (GLP-1R Emax 106%, Coskun 2022 Table S2

How might the weekly dosing regimen of semaglutide impact patient adherence when compared to daily diabetes medication usage